Advertisement

Biocompatibility — Principles

  • Raymond M. Hakim
  • Jonathan Himmelfarb

Abstract

The contact of blood with biomaterials used in hemodialysis, elicits an organized inflammatory response that involves the activation of the body’s defense against ‘nonself’. These reactions include not only the enzymatic cleavage of proteins, such as the complement, contact and coagulation pathways, but in addition, cellular events that are part of the inflammatory response. Activation of these cellular pathways can result indirectly from the products of activation of these protein pathways or from the direct interaction of these cells with foreign surfaces. In this chapter, several of these inflammatory responses which are relevant to the hemodialysis procedure will be outlined. The clinical relevance of these reactions are detailed elsewhere in this volume

Keywords

Complement Activation Hemodialysis Membrane Hageman Factor Complement Effector Cytolytic Lymphocyte 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schreiber RD, Muller-Eberhard HJ: Complement and renal disease. in Immunologic Mechanisms of Renal Disease. Vol 3, edited by Wilson CB, Brenner BM, Stein JH, New York, Churchill Livingstone, 1979, p 67Google Scholar
  2. 2.
    Muller-Eberhard HJ: Molecular organization and function of the complement system. Ann Rev Biochem 57: 321, 1988PubMedCrossRefGoogle Scholar
  3. 3.
    Pangbum MK, Schreiber RD, Muller-Eberhard HJ: Formation of the initial C3 convertase of the alternative complement pathway: acquisition of C3b-like activities by spon-taneous hydrolysis of the putative thioester in native C3. J Exp Med 154: 856, 1981CrossRefGoogle Scholar
  4. 4.
    Esser AF: The membrane attack pathway of complement. Year Immunol 6: 229, 1989PubMedGoogle Scholar
  5. 5.
    Pangburn MK: Initiation and activation of the alternative pathway of complement. in Cytolytic Lymphocytes and Complement Effectors of the Immune System, edited by Podack ER, Boca Raton, CRC Press, 1988, p 41Google Scholar
  6. 6.
    Podack ER: Assembly and structure of the membrane attack (MAC) of complement. in Cytolytic Lymphocytes and Complement Effectors of the Immune System, edited by Podack ER, Boca Raton, CRC Press, 1988, 173Google Scholar
  7. 7.
    Dalmasso AP, Benson BA: Pore size of lesions induced by complement on red cell membranes and its relation to C5b-8, C5b-9 and Poly C9. in Cytolytic Lymphocytes and Complement Effectors of the Immune System, edited by Podack ER, Boca Raton, CRC Press, 1988, p207Google Scholar
  8. 8.
    Young JD-E, Cohn ZA, Podack ER: Pore size and func-tional properties of defined MAC and poly C9 complexes: reconstitution into model lipid membranes. in Cytolytic Lymphocytes and Complement Effectors of the Immune System, edited by Podack ER, Boca Raton, CRC Press, 1988, p221Google Scholar
  9. 9.
    Shin ML, Carney DF: Mechanisms of the cellular defense response of nucleated cells to membrane attack by complement, in Cytolytic Lymphocytes and Complement Effectors of the Immune System, edited by Podack ER, Boca Raton, CRC Press, 1988, p229Google Scholar
  10. 10.
    Seeger W, Suttorp N, Hellwig A, Bhakdi S: Noncytolytic terminal complement complexes may serve as calcium gates to elicit leukotriene B4 generation in human poly-morphonuclear leukocytes. J Immunol 137: 1286, 1986PubMedGoogle Scholar
  11. 11.
    Hansch GM, Seitz M, Martinotti G, Betz M, Rauterberg EW, Gemsa D: Macrophages release arachidonic acid, prostaglandin E2, and thromboxane in response to late complement components. J Immunol 133: 2145, 1984PubMedGoogle Scholar
  12. 12.
    Salama A, Mueller-Eckhardt C, Boschek B, Bhakdi S: Haemolytic ‘efficiency’ of C5b-9 complexes in drug-induced immune haemolysis: role of cellular C5b-9 dis-tribution. Br J Haematol 65: 217, 1987PubMedGoogle Scholar
  13. 13.
    Weidmer T, Esmon CT, Sims PJ: On the mechanisms by which complement proteins C5b-9 increase platelet pro-thrombinase activity. J Biol Chem 261: 14587, 1986Google Scholar
  14. 14.
    Rinder CS, Bohnert J, Rinder HM, Mitchell J, Ault K, Hillman R: Platelet activation and aggregation during car-diopulmonary bypass. Anesthesiology 75: 388, 1991PubMedCrossRefGoogle Scholar
  15. 15.
    Chenoweth DE: Complement activation in extracorporeal circuits. Ann NY Acad Sci 516: 306, 1987PubMedCrossRefGoogle Scholar
  16. 16.
    Chenoweth DE: The properties of human C5a anaphyla-toxin. The significance of C5a formation during hemodialysis. Contrib Nephrol 59: 51, 1987PubMedGoogle Scholar
  17. 17.
    Chenoweth DE: Complement activation produced by biomaterials. Trans Am Soc Artif Intern Organs 32: 226, 1986Google Scholar
  18. 18.
    Chenoweth DE: Complement activation produced by biomaterials. Artif Organs 12: 502, 1991Google Scholar
  19. 19.
    Janatova J, Cheung AK, Parker CJ: Biomedical polymers differ in their capacity to activate complement. Complement Inflamm 8: 61, 1991PubMedGoogle Scholar
  20. 20.
    Cheung AK: Biocompatibility of hemodialysis membranes. J Am Soc Nephrol 1: 150, 1990PubMedGoogle Scholar
  21. 21.
    Hakim RM, Fearon DT, Lazarus JM: Biocompatibility of dialysis membranes: effects of chronic complement activation. Kidney Int 26: 94, 1984CrossRefGoogle Scholar
  22. 22.
    Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW: Complement activation during cardiopulmonary bypass. Evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 304: 497, 1981PubMedCrossRefGoogle Scholar
  23. 23.
    Meri S, Pangburn MK: Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci USA 87: 3982, 1990PubMedCrossRefGoogle Scholar
  24. 24.
    Deppisch R, Ritz E, Hansch GM, Schols M, Rauterberg EW: Bioincompatibility-Perspectives in 1993. Kidney Int 54;44: S77, 1994Google Scholar
  25. 25.
    Cheung AK, Parker CJ, Wilcox L, Janatova J: Activation of the alternative pathway of complement by hemodialysis membranes. Kidney Int 36: 257, 1989PubMedCrossRefGoogle Scholar
  26. 26.
    Cheung AK, Chenoweth DE, Otsuka D, Henderson LW: Compartmental distribution of complement activation products in artificial kidneys. Kidney Int 30: 74, 1986PubMedCrossRefGoogle Scholar
  27. 27.
    Oppermann M, Kurts C, Zierz R, Quentin E, Weber MH, Gotze O: Elevated plasma levels of the immunosuppressive complement fragment Ba in renal failure. Kidney Int 40: 939, 1991PubMedCrossRefGoogle Scholar
  28. 28.
    Maillet F, Kazatchkine MD: Specific antibiotics enhance alternative complement pathway activation by cuprophan. Nephrol Dial Transplant 6: 193, 1991PubMedGoogle Scholar
  29. 29.
    Hugli TE: Biochemistry and biology of anaphylatoxins. Comp 3: 111, 1986Google Scholar
  30. 30.
    Haeffner-Cavaillon N, Cavailon JM, Laude M, Kazatch-kine MD: C3a (C3adesArg) induces production and release of interleukin-1 by cultured human monocytes. J Immunol 139: 794, 1987PubMedGoogle Scholar
  31. 31.
    Cheung AK, Parker CJ, Janatova J: Analysis of the complement C3 fragments associated with hemodialysis membranes. Kidney Int 35: 576, 1989PubMedCrossRefGoogle Scholar
  32. 32.
    Deppisch R, Schmitt V, Bommer J, Hansch G, Ritz E, Rauterberg EW: Fluid phase generation of terminal complement complex as a novel index of biocompatibility. Kidney Int 37: 696, 1990PubMedCrossRefGoogle Scholar
  33. 33.
    Salzman EW: Interaction of blood with artificial surfaces. in Hemostasis and Thrombosis, edited by Colman RW, Hirsh J, Marder VJ, Salzman EW, New York, Lippincott, 1987, p 1335Google Scholar
  34. 34.
    Schmeier AH: Contact activation. in Thrombosis and Hemorrhage, edited by Loscalzo J, Schafer AI, Boston, Blackwell Scientific Publications, 1994, p 87Google Scholar
  35. 35.
    Parnes EL, Shapiro WB: Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer. Kidney Int 40: 1148, 1991Google Scholar
  36. 36.
    Schulman G, Hakim R, Arias R, Silverberg M, Kaplan AP, Arbeit L: Bradykinin generation by dialysis membranes: possible role in anaphylactic reaction. J Amer Soc Neph 3: 1563, 1993Google Scholar
  37. 37.
    Tielemans C, Madhoun P, Lenaers M, Schandene L, Goldman M, Vanderweghem JL: Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors. Kidney Int 38: 982, 1990PubMedCrossRefGoogle Scholar
  38. 38.
    Verresen L, Waer M, Vanrenterghem Y, Michielsen P: Angiotensin-converting-enzyme inhibitors and anaphylac-toid reactions to high-flux membrane dialysis. Lancet 336: 1360, 1990PubMedCrossRefGoogle Scholar
  39. 39.
    Lemke HD, Fink E: Accumulation of bradykinin formed at the AN69 or polyacrylonitrile 17DX membrane is due tot he presence of an angiotensin-converting enzyme inhibitor in-vitro (Abstract). Blood Purif 10: 92, 1992Google Scholar
  40. 40.
    Williams DF: Blood physiology and biochemistry: hemostasis and thrombosis. in Blood Compatibility, Vol I edited by Williams DF, Boca Raton. CRC Press, 1987, p 5Google Scholar
  41. 41.
    Carretero O: Vasoactive mediators: kinins and kallikreins. in Manual of Vascular Mediators, edited by Ward P, New York, Hospital Practice, 1993Google Scholar
  42. 42.
    Pegues DA, Beck-Sague CM, Woollen SW et al.: Ana-phylactoid reactions associated with reuse of hollow-fiber hemodialyzers and ACE inhibitors. Kidney Int 42: 1232, 1992PubMedCrossRefGoogle Scholar
  43. 43.
    Mohammad SF: Extracorporeal thrombogenesis: mechanisms and prevention. in Replacement of Renal Function by Dialysis, Vol 3, edited by Maher JF, Boston, Kluwer Academic Publishers, 1989, p 229Google Scholar
  44. 44.
    Chuang HYK, Mohammad SF, Sharma NC, Mason RG: Interaction of human a-thrombin with artificial surfaces and reactivity of adsorbed a-thrombin. J Biomed Mater Res 14: 467, 1980PubMedCrossRefGoogle Scholar
  45. 45.
    Lindon J, Rosenberg R, Merrill E, Salzman E: Interaction of human platelets with heparinized agarose gel. J Lab Clin Med 91: 47, 1978PubMedGoogle Scholar
  46. 46.
    Mohammad SF, Anderson WH, Smith JB, Chuang HYK, Mason RG: Effects of heparin on platelet aggregation, release reaction and thromboxane A2 production. Am J Pathol 104: 132, 1981PubMedGoogle Scholar
  47. 47.
    Kaplan KL, Owen J: Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 57: 199, 1981Google Scholar
  48. 48.
    Cheung AK, Parker CJ, Janatova J, Brynda E: Modulation of complement activation on hemodialysis membranes by immobilized heparin. J Am Soc Nephrol 8: 1328, 1992Google Scholar
  49. 49.
    Kaplow L, Goffinet J: Profound neutropenia during the early phase of hemodialysis. JAMA 203: 133, 1968CrossRefGoogle Scholar
  50. 50.
    Toren M, Goffinet JA, Kaplow LS: Pulmonary bed seques-tration of neutrophils during hemodialysis. Blood 36: 337, 1970PubMedGoogle Scholar
  51. 51.
    Craddock PR, Fehr J, Brigham KL, Kronenberg RS, Jacob HS: Complement and leukocyte-mediated pulmonary dys-function in hemodialysis. N Eng J Med 296: 769, 1977CrossRefGoogle Scholar
  52. 52.
    Craddock PR, Fehr J, Dalmasso AP, Brigham K, Jacob HS: Hemodialysis leukopenia: pulmonary vascular leukostasis resulting from complement activation by dialyzer cello-phane membranes. J Clin Invest 59: 879, 1977PubMedCrossRefGoogle Scholar
  53. 53.
    Schaefer RM, Herfs N, Ormanns W, Horl WH, Heidland A: Change of elastase and cathepsin G content in polymor-phonuclear leukocytes during hemodialysis. Clin Nephrol 29: 307, 1988PubMedGoogle Scholar
  54. 54.
    Himmelfarb J, Zaoui P, Hakim RM, Holbrook D: Modu-lation of granulocyte LAM1 and MAC1 during dialysis-a prospective, randomized controlled trial. Kidney Int 41: 388, 1992PubMedCrossRefGoogle Scholar
  55. 55.
    Alvarez PR, Campanero MR, Pariaso V, Landazuri MO, Sanchez-Madrid F: Differentially regulated cell surface expression of leukocyte adhesion receptors on neutrophils. Kidney Int 40: 899, 1991PubMedCrossRefGoogle Scholar
  56. 56.
    Arnaout MA: Structure and function of the leukocyte adhe-sion molecules CD11/CD18. Blood 75: 1037, 1990PubMedGoogle Scholar
  57. 57.
    Arnaout MA, Hakim RM, Todd RF, Dana N, Colten HR: Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med 312: 457, 1985PubMedCrossRefGoogle Scholar
  58. 58.
    Skubitz KM, Craddock PR: Reversal of hemodialysis granulocytopenia and pulmonary leukostasis: a clinical manifestation of selective down-regulation of granulocyte responses to C5a desArg. J Clin Invest 67: 1383, 1981PubMedGoogle Scholar
  59. 59.
    Craddock PR, Hammerschmidt DE: Complement-mediated granulocyte activation and down-regulation during hemodialysis. ASAIO J 7: 50, 1984Google Scholar
  60. 60.
    Gardinalli M, Hugli TE, Ward DM, gostoni A: PMN C5a-receptor-down-regulation is not involved in recovery from C5a-induced neutropenia. ASAIO J 10: 482, 1987Google Scholar
  61. 61.
    Brubaker LH, Nolph KD: Mechanism of recovery from neutropenia induced by hemodialysis. Blood 38: 623, 1971PubMedGoogle Scholar
  62. 62.
    Smith EKM, Jobbins K: Observation on neutropenia asso-ciated with hemodialysis. Br Med J 4: 70, 1969PubMedGoogle Scholar
  63. 63.
    Lewis SL, van Epps DE, Chenoweth DE: Leukocyte C5a receptor modulation during hemodialysis. Kidney Int 31: 112, 1987PubMedCrossRefGoogle Scholar
  64. 64.
    Himmelfarb J, Gerard NP, Hakim RM: Intradialytic modulation of granulocyte C5a receptors. J Am Soc Nephrol 2: 920, 1991PubMedGoogle Scholar
  65. 65.
    Butcher EC: Cellular and molecular mechanisms that direct leukocyte traffic. Am J Path 136: 3, 1990PubMedGoogle Scholar
  66. 66.
    Springer TA: Adhesion receptors of the immune system. Nature 346: 425, 1990PubMedCrossRefGoogle Scholar
  67. 67.
    Kishimoto TK, Jutila MA, Berg EL, Butcher EC: Neu-trophil MAC-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. Science 245: 1238, 1989PubMedCrossRefGoogle Scholar
  68. 68.
    Lawrence MB, Springer TA: Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell 65: 859, 1991PubMedCrossRefGoogle Scholar
  69. 69.
    Cheung AK, Hohnholt M, Gilson J: Adherence of neutrophils to hemodialysis membranes: Role of complement receptors. Kidney Int 40: 1123, 1991PubMedCrossRefGoogle Scholar
  70. 70.
    Cheung AK, Parker CJ, Hohnholt M: Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro. Kidney Int 46: 1680, 1994CrossRefGoogle Scholar
  71. 71.
    Himmelfarb J, Lazarus JM, Hakim RM: Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis 17: 271, 1991PubMedGoogle Scholar
  72. 72.
    Vanholder R, Ringoir S, Dhondt A, Hakim R: Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study. Kidney Int 39: 320, 1991PubMedCrossRefGoogle Scholar
  73. 73.
    Schamier AH, Silverberg M, Kaplan AP, Colman RW: Contact activation and its abnormalities. in Hemostasis and Thrombosis, Vol 2, edited by Colman RW, Hirsh J, Marder VJ, Salzman WE, Philadelphia, JB Lippincott Co, 1987Google Scholar
  74. 74.
    Wachtfogel TY, Kuchich U, James HL, Scott CF, Schapi-ra M, Zimmerman M, Cohen AB, Colman RW: Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest 72: 1672, 1983PubMedGoogle Scholar
  75. 75.
    Wachtfogel YT, Pixley RA, Kucich U, Abrams W, Wein-baum G, Schapira M, Colman RW: Purified plasma factor XIIa aggregates human neutrophils and causes degranula-tion. Blood 67: 1731, 1986PubMedGoogle Scholar
  76. 76.
    Van Oeverin W, Jansen NJG, Bidstrup BP, Royston D, Westaby S, Neuhof H, Wildevuur CRH: Effects of apro-tinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 44: 640, 1987CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Raymond M. Hakim
    • 1
  • Jonathan Himmelfarb
    • 2
  1. 1.Renal DivisionS-3307 MCN, VUMCNashvilleUSA
  2. 2.Maine Nephrology Associates P.A.PortlandUSA

Personalised recommendations